- Home
- UWMC vs VOR Comparison
UWMC vs VOR Comparison
Compare UWMC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UWMC | VOR |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | 9100 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.3M | 813.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | UWMC | VOR |
|---|---|---|
| Price | $2.21 | $14.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $6.13 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 23.5M | 770.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.60 | N/A |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $1.11 |
| 52 Week High | $7.14 | $49.95 |
Technical Indicators
Market Signals| Indicator | UWMC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 19.87 | 50.83 |
| Support Level | N/A | $13.73 |
| Resistance Level | $4.01 | $14.73 |
| Average True Range (ATR) | 0.17 | 1.01 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 8.29 | 66.78 |
Price Performance
Historical ComparisonAbout UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.